Compare SPRO & CRMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | CRMT |
|---|---|---|
| Founded | 2013 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 105.4M |
| IPO Year | 2017 | 2026 |
| Metric | SPRO | CRMT |
|---|---|---|
| Price | $2.24 | $12.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | ★ 261.3K | 192.6K |
| Earning Date | 03-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 111.81 | ★ 147.36 |
| EPS | ★ 0.15 | N/A |
| Revenue | $66,802,000.00 | ★ $1,390,932,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.57 |
| P/E Ratio | $15.53 | ★ N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $0.51 | $11.04 |
| 52 Week High | $3.09 | $62.55 |
| Indicator | SPRO | CRMT |
|---|---|---|
| Relative Strength Index (RSI) | 39.83 | 32.69 |
| Support Level | $2.15 | $11.04 |
| Resistance Level | $2.44 | $13.87 |
| Average True Range (ATR) | 0.13 | 1.27 |
| MACD | -0.02 | 0.17 |
| Stochastic Oscillator | 4.35 | 22.41 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.